Many children with fragile X syndrome have had poorer academic performance, worsening mental health problems, and more difficulties with…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A new tool that uses artificial intelligence (AI) to analyze healthcare records may aid in the early diagnosis of…
A new fund at the University of California, Davis (UC Davis) MIND Institute seeks to speed up turning new research…
Treatment with Anavex2-73 (blarcamesine), an experimental therapy that Anavex Life Sciences is developing to treat fragile X syndrome…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to Neuronascent‘s investigational therapy NNI-351 for…
In an effort to both increase accuracy and remove offensive language in the name of FMR1 — the gene…
In people with fragile X-associated tremor/ataxia syndrome (FXTAS), a condition related to fragile X syndrome that develops late in…
Unusually low amounts of cholesterol in cellular structures called lipid rafts may contribute to behavioral differences seen in people with…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Behavioral problems such as hyperactivity and aggression are generally more frequent in younger children with fragile X syndrome, becoming…